Sugi Predict

Sugi Predict / Compounds / SCHEMBL259433

SCHEMBL259433

SCHEMBL259433

CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@]3(O)CCC(=O)O)[C@H]12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 5/20 0.65
▸ LMNA P02545 4/20 0.65
▸ NR3C1 P04150 2/20 0.65
▸ PGR P06401 2/20 0.65
▸ CYP3A4 P08684 1/20 0.65
▸ NFKB1 P19838 1/20 0.65
▸ HIF1A Q16665 1/20 0.65
▸ ABCB11 O95342 1/20 0.65
▸ ESR1 P03372 1/20 0.65
▸ CHRM2 P08172 1/20 0.65
▸ ABCB1 P08183 1/20 0.65
▸ NR3C2 P08235 1/20 0.65
▸ CYP2C19 P33261 1/20 0.65
▸ ADRA1A P35348 1/20 0.65
▸ OPRK1 P41145 1/20 0.65
▸ HTR2B P41595 1/20 0.65
▸ ESR2 Q92731 1/20 0.65
▸ SLC47A1 Q96FL8 1/20 0.65
▸ RAB9A P51151 1/20 0.65
▸ MAPT P10636 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL259434 1.00 AR (0.65) ARLMNANR3C1PGRCYP3A4
SCHEMBL8846925 1.00 AR (0.65) ARLMNANR3C1PGRCYP3A4
SCHEMBL5296168 1.00 AR (0.65) ARLMNANR3C1PGRCYP3A4
SCHEMBL8846916 1.00 AR (0.65) ARLMNANR3C1PGRCYP3A4
SCHEMBL18812341 0.94 LMNA (0.66) ARLMNANR3C1PGRCYP3A4
SCHEMBL11644576 0.89 LMNA (0.65) ARLMNANR3C1PGRCYP3A4
SCHEMBL11644583 0.89 LMNA (0.65) ARLMNANR3C1PGRCYP3A4
SCHEMBL7787111 0.89 AR (0.62) ARLMNANR3C1PGRCYP3A4
SCHEMBL9404138 0.89 AR (0.62) ARLMNANR3C1PGRCYP3A4
SCHEMBL11646428 0.86 AR (0.61) ARLMNANR3C1PGRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210038563-A1 NEW SPIRONOLACTONE FORMULATIONS AND THEIR USE APIDEL SA (CH) 2021-02-11 — — US claimed
WO-2025068481-A1 SPIRONOLACTONE EYE DROP FORMULATIONS Institut National de la Santé et de la Recherche Médicale (FR) 2025-04-03 — — WO disclosed
EP-4376821-A1 TREATING CANCERS WITH COMBINATIONS OF SPIRONOLACTONE AND ACYLFULVENES Lantern Pharma Inc. (US) 2024-06-05 — — EP disclosed
US-20240173337-A1 METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA APNIMED, INC. (DELAWARE) 2024-05-30 — — US disclosed
CN-117881396-A Treatment of cancer with spirolactone and acyl fulvene combinations 蓝腾制药公司 2024-04-12 — — CN disclosed
WO-2023010107-A1 TREATING CANCERS WITH COMBINATIONS OF SPIRONOLACTONE AND ACYLFULVENES LANTERN PHARMA INC. (US) 2023-02-02 — — WO disclosed
US-11358931-B2 Selective androgen receptor modulators (SARMs) and uses thereof LIGAND PHARMACEUTICALS INCORPORATED (US) 2022-06-14 — — US disclosed
US-20210038563-A1 NEW SPIRONOLACTONE FORMULATIONS AND THEIR USE APIDEL SA (CH) 2021-02-11 — — US disclosed
US-20200361866-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2020-11-19 — — US disclosed
US-10730831-B2 Selective androgen receptor modulators (SARMs) and uses thereof LIGAND PHARMACEUTICALS INCORPORATED (US) 2020-08-04 — — US disclosed
US-5696133-A ADMINISTERING COMPOUND WHICH MODULATES ACTIVITY OF PROGESTERONE RECEPTOR LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-12-09 — — US disclosed
US-5696130-A Tricyclic steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-12-09 — — US disclosed
US-5693647-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-12-02 — — US disclosed
US-5693646-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-12-02 — — US disclosed
US-5688808-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-11-18 — — US disclosed
US-5688810-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-11-18 — — US disclosed
EP-0800519-A1 STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS, INC. (US) 1997-10-15 — — EP disclosed
WO-1996019458-A2 STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INCORPORATED (US) 1996-06-27 — — WO disclosed
US-5286494-A Medicinal agents with sustained action SCHERING AKTIENGESELLSCHAFT (DE) 1994-02-15 — — US disclosed
US-4213902-A Process for producing steroidal 7α-acylthio-4-en-3-ones MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) 1980-07-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361866-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF AR, NR5A1, SHBG AR 1/4885LMNA 3992/4885NR3C1 26/4885
US-20210038563-A1 NEW SPIRONOLACTONE FORMULATIONS AND THEIR USE REN, NR3C2, PKD1 AR 140/4885LMNA 511/4885NR3C1 356/4885
US-11358931-B2 Selective androgen receptor modulators (SARMs) and uses thereof AR, NR5A1, SHBG AR 1/4885LMNA 4044/4885NR3C1 31/4885
US-10730831-B2 Selective androgen receptor modulators (SARMs) and uses thereof AR, NR5A1, SHBG AR 1/4885LMNA 4044/4885NR3C1 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.